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Epidemiological studies suggest a correlation between sever-
ity of acquired immunodeficiency syndrome (AIDS) and sele-
nium deficiency, indicating a protective role for this anti-oxi-
dant during HIV infection. Here we demonstrate that
thioredoxin reductase-1 (TR1), a selenium-containing pyridine
nucleotide-disulfide oxidoreductase that reduces protein disul-
fides to free thiols, negatively regulates the activity of the HIV-1
encoded transcriptional activator, Tat, in human macrophages.
We used a small interfering RNA approach as well as a high
affinity substrate of TR1, ebselen, to demonstrate that Tat-de-
pendent transcription and HIV-1 replication were significantly
increased in human macrophages when TR1 activity was
reduced. The increase in HIV-1 replication in TR1 small inter-
feringRNA-treated cellswas independent of the redox-sensitive
transcription factor, NF-B. These studies indicate that TR-1
acts as a negative regulator ofTat-dependent transcription. Fur-
thermore, in vitro biochemical assays with recombinant Tat
protein confirmed that TR1 targets two disulfide bonds within
the Cys-rich motif required for efficient HIV-1 transactivation.
Increasing TR1 expression along with other selenoproteins by
supplementing with selenium suggests a potential inexpensive
adjuvant therapy for HIV/AIDS patients.
The physiological functions of the micronutrient selenium
are mediated through a co-translational insertion of selenocys-
teine (Sec),3 into specific proteins (1, 2). Commonly studied
selenoproteins such as the glutathione peroxidases, thiore-
doxin reductases (TR), and deiodinases share a redox mecha-
nism that is driven by Sec present in the active site making
selenium a required vital nutrient. As a specific example, sele-
nium deficiency has been strongly and independently associ-
ated with disease progression and mortality in HIV-infected
individuals, increased genital shedding of HIV DNA, and
increased risks of fetal and child mortality as well as intrapar-
tum mother-to-child transmission (3–6). Recent studies have
demonstrated that daily selenium supplementation of HIV-1
positive individuals suppresses the progression of HIV-1 viral
burden, provides improvement of CD4 counts (7), increases
vigor (8), decreases anxiety, and reduces the need for hospital-
ization when compared with those receiving a placebo (9–11).
HIV-1 infection alters the expression of selenoproteins,
including TR (12). TRs are enzymes belonging to the flavopro-
tein family of pyridine nucleotide-disulfide oxidoreductases
that includes lipoamide dehydrogenase, glutathione reductase,
and mercuric ion reductase (1, 13, 14). Each monomer of TR
includes a FAD prosthetic group, an NADPH binding site, and
a selenneylsulfide active site. This active site is formed from the
conserved Cys-Sec sequence, which is reduced to a selenolthiol
by electrons from the redox-active disulfide of the other sub-
unit (15, 16). Electrons are transferred from NADPH to the
active site of the disulfide of TR via FAD, which then reduces
the substrate. TRs exhibit catalytic redox activity toward thi-
oredoxin (Trx), a group of small redox active proteins in the
mass range of 10–12 kDa, which in turn catalyze thiol-disulfide
exchange to reduce key Cys residues in transcription factors
(14). Extracellular Trx inhibits the production of HIV-1,
whereas its degradation product, eosinophil cytotoxicity-en-
hancing factor, promotes HIV-1 production (17). Apart from
Trx, cytosolic TR (TR1) exhibits broad substrate specificity
reducing cytotoxic protein NK-lysin, tumor suppressor protein
p53, and non-protein substrates such as lipoic acid, lipid
hydroperoxides, vitamin K3, dehydroascorbic acid, and the
ascorbyl free radical (1, 18).
Tat is an HIV-encoded transactivating protein that is
required for virus replication. Tat binds to a RNA stem loop
structure (TAR) and recruits the positive transcription elonga-
tion factor, P-TEFb, to the HIV long terminal repeat (LTR),
increasing RNA polymerase II processivity (19, 20). In the
absence of Tat, transcription is impaired, leading to the accu-
mulation of prematurely terminated short transcripts (21, 22).
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The primary structure of Tat is made up of 101 amino acids.
Based onmutagenesis studies, the Cys-rich region (amino acids
20–39) has been demonstrated to be necessary for Tat activity
(23, 24). Furthermore, Koken et al. (25) have shown that the
transcriptionally active formof Tat is amonomer, and reducing
agents strongly inhibit Tat activity, suggesting that Cys residues
inTat form intramolecular disulfide bonds. Similarly, increased
transactivation activity was seen in bacterially expressed Tat
that was subjected to slow-protein refolding, which permits the
formation of disulfide bonds (26). These data suggest that the
activity of Tat is governed in part by Cys groups via the forma-
tion of disulfide bonds and that Tat is sensitive to the redox
state of the cell. Here, we report that TR1 targets the disulfide
bonds in Tat and functions as a negative regulator of Tat-de-
pendent proviral transcription.
MATERIALS ANDMETHODS
Cell Culture—The human U937 promonocytic cell line
(ATCC, Manassas, VA) was cultured in RPMI 1640 medium
supplemented with 5% defined fetal calf serum (Hyclone), 100
units/ml penicillin, 100 g/ml streptomycin, and 0.2 M L-gluta-
mine. Peripheral blood macrophages were isolated from whole
blood obtained from healthy HIV-1-seronegative donors.
Mononuclear cells were obtained by differential centrifugation
using a Ficol/Hystopaque (Sigma-Aldrich) gradient and adher-
ence to plastic culture flasks as previously described (27).
Macrophages were separated from other cells by an initial
adherence to plastic culture flasks overnight. After removing
nonadherent cells, monocytes were cultured for 5–10 days to
mature into monocyte-derived macrophages (MDM). All pro-
tocols were preapproved by the IRB at Penn State University.
Fetal calf serum lots containing low selenium were selected for
the study. Selenium was measured using atomic absorption
spectrometry. The basal media (containing 7 nM selenium) was
supplemented with selenium in the form of sodium selenite.
Jurkat CD4T-cells stably expressingHIV-1Tatwere obtained
from Drs. Antonella Caputo, William Haseltine, and Joseph
Sodorski through the NIH AIDS Research and Reagent Pro-
gram. The cells were cultured in RPMI 1640 medium contain-
ing 10% defined fetal calf serum and 800 g/ml G418.
Expression and Activity of TR—U937 cells were cultured in
basal media with or without exogenously added selenium for 1
week with three media changes in between. The washed cell
pellets were lysed with mammalian protein extraction reagent
(M-PER; Pierce) and clarified by centrifugation at 16,000 g at
4 °C for 15min. Cell lysates were used in immunoblot and enzy-
matic assays for TR. Assays for cytosolic TR activity in these
lysates were performed as described by Holmgren and Bjornst-
edt (28), where recombinant Tat (rTat) was substituted for Trx
in the assay. 0.1M purified rat liver TR1 from Sigma was used.
Change in the absorbance at 314 nm was used to calculate the
activity.
Transient Transfections, siRNA, and Luciferase Assay—Rep-
lication competent HXB.2, bacterial and mammalian HIV-1
Tat expression vectors, pTat86R His (29), and pCI-Tat1 (30)
were obtained from theAIDS Research Reference Reagent Pro-
gram, Division of AIDS, NIAID, National Institutes of Health.
pCI vector (Promega, Madison, WI) was used as an empty vec-
tor control. LTR reporter constructs, LTR-Luc (wild-type205
LTR),TARLTR-Luc (205 LTR lacking the TAR region), and
BLTR-Luc (205LTR lacking theNF-Bbinding sites)were
prepared as previously described (31). DNA for transfections
was prepared using plasmid purification systems from Marli-
gen Biosciences (Ijamsville, MD) following protocols provided
by themanufacturer. Transfection of U937 cells was performed
using TransIT-Jurkat transfection reagent from Mirus (Madi-
son, WI). Transfection efficiency was assessed by co-transfect-
ing pEGFP-N3 (Clontech, Palo Alto, CA) and monitoring
enhanced green fluorescence protein expression by fluores-
cence microscopy. Cell viability was confirmed by trypan blue
staining. siRNA for TR1 as well as siRNA control were recon-
stituted based on the manufacturer’s guidelines (Dharmacon).
Luciferase assays were performed using a commercial lucifer-
ase assay kit (Promega) and a TD-20/20 luminometer (Turner
BioSystems, Sunnyvale, CA). U937 cells were infected with
HIV-Luc virus (1 106 infectious particles/1 106 cells). The
next day cells were transfected with TR1 or control siRNA
using the Amaxa nucleofector system, and luciferase activity
was measured 72 h post-infection.
Generation of HIV Infectious Titers, Infections, and Trans-
duction of Macrophages—Infectious HXB.2 virus was gener-
ated by cotransfecting 293T cells with 15g of HXB.2 cDNA, 3
g of vesicular stomatitis virus-glycoprotein, and 3 g of RSV-
Rev by calcium phosphate transfection (32). Transfection effi-
ciency was assessed by measuring p24 levels (p24 ELISA,
PerkinElmer Life Sciences). We consistently generated titers of
1.0 106 infectious particles/ml. Supernatants were collected
and filtered through 0.45-m syringe filter (Whatman, Clifton,
NJ). One ml of undiluted virus stock was added to 1.0 106
U937 cells or human MDMs (differentiated 10 days) for 24 h
and then replacedwith freshmedia. Cells were then transfected
with TR1 siRNA using the Amaxa nucleofector system and
were subjected to luciferase assays 3–5 days post-infection. For
some experiments transfected cells were cultured in the pres-
ence or absence of ebselen (5 M; Sigma) or DMSO. Superna-
tants were collected at 4 days post-infection and assayed for
viral replication by p24 ELISA. To assess the effect of selenium
supplementation on p24 levels, 1.0 106 U937 cells were cul-
tured in a selenium-deficient media and infected with HXB.2
for 24 h followed by media changes containing selenium from
0.05 M to 1 M. After 3 days, the culture media supernatants
were used to measure p24 levels.
Immunoblots—MDMs and U937 cells were washed twice
with phosphate-buffered saline, and protein extracts were pre-
pared by treating cells with M-PER reagent (Pierce) at 4 °C for
30 min. Lysates were mixed with 2 SDS loading buffer con-
taining dithiothreitol and heated at 100 °C for 5 min before
resolving by SDS-PAGE (%T  4–20) followed by immuno-
blotting onto a nitrocellulose membrane. Rabbit polyclonal
antibodies against TR1 and GPX1 (Abcam) were used to ana-
lyze expression of the two selenoproteins. Horseradish peroxi-
dase-conjugated goat anti-rabbit IgG (Sigma-Aldrich) was used
as the secondary antibody. To normalize loading, membranes
were treated with Western blot stripping buffer (Pierce) and
reprobed with anti--actin or anti- glyceraldehyde-3-phos-
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phate dehydrogenase followed by an appropriate horseradish
peroxidase-conjugated secondary antibody.
Expression, Purification, and Refolding of rTat—rTat was
expressed in Escherichia coli transformedwith pTat86RHis as a
His-tagged fusion protein using the autoinduction system
(Novagen). The purification of rTat was performed using the
method of Kirsch et al. (26) with some modifications. Briefly,
the E. coli pellet from a 24-h culture was lysed in 6 M guanidine-
HCl for 12 h. All steps were performed at 4 °C unless otherwise
mentioned. The cleared cell lysate was applied to a nickel-ni-
trilotriacetic acid column (Novagen) and developed as
described by Kirsch et al. (26). The eluate was dialyzed against
0.1 N HCl for 2 days at 4 °C followed by an overnight lyophili-
zation. The lyophilized powder was reconstituted in 6 M urea
followed by reduction of the thiols with tris[2-carboxyeth-
yl]phosphine (25 mol/mol of Tat) in the dark for 8 h at room
temperature as per the instructions of the supplier (Pierce). The
mixture was subjected to sequential dialysis in 0.1 M phosphate
buffer (pH 6.3) containing 4M urea, 2 M urea, and finally in 0.1 M
phosphate buffer (pH 4.3) containing 200 mMNaCl. The dialy-
sate was filtered through 0.45-m filter and stored in small
aliquots at20 °C for further use. Typical yields from a liter of
bacterial culturewere10mgof pureTat, based onSDS-PAGE
(95%).
Analysis of rTat Activity—U937 cells were transfected with 2
g of LTR-Luc or an irrelevant reporter plasmid (pSV2-Luc) as
a control by transient transfection. Cells were then treated with
2 g of rTat or buffer alone, and luciferase activity was meas-
ured 48 h post-transfection as an indication of proviral tran-
scription. After transfections, trypan blue staining was per-
formed to control for cell viability. Transfections were
performed in triplicate, and the data are presented as the % of
luciferase with luciferase activity in the cells lacking Tat set at
100%.
Quantifying Free Cys Thiols in rTat—Purified and refolded
rTat, as described above, was used in the standard Ellman’s
reagent (5,5-dithiobis(2-nitrobenzoic acid) assay as described
by the supplier (Pierce). The concentration of rTat was 2 M,
whereas the concentration of rat liver TR1 (Sigma) was 100 nM
in the reaction mixture containing 0.008% bovine serum albu-
min, 4.3 mM EDTA, 0.43 mM NADPH in a total of 1 ml of
phosphate buffer (pH 7.0) at 37 °C. Additional controls
included heat-denatured TR1 and TR1 without NADPH. Free
thiol (SH) groups in rTat were estimated before and after
reduction by TR, reaction with heat-denatured TR, and reac-
tion on ice (2 °C) using the standard Ellman’s reagent with
freshly prepared L-cysteine solution as a calibration standard
(0–80 M).
Redox Western Blot Analysis—rTat protein (20 M) was
reacted with TR1 (100 nM, from Sigma) in the presence of 0.5
mMNADPH, 5mM EDTA, 0.1 mg/ml bovine serum albumin in
100mM phosphate buffer (pH 7.0) for 1 h at room temperature.
The resultant mixture was then incubated with 25 mM AMS
(4-acetamido-4-maleimidylstilbene-2,2-disulfonic acid; 250
mM stock in DMSO) for 30 min at 4 °C followed by 10 min at
37 °C. Themixturewas subjected to a non-denaturing and non-
reducing PAGE (%T  18) followed by Western blotting with
anti-Tat polyclonal antibodies. rTat (50 nM) reduced with 2.5
mM DTT and subsequently treated with AMS was used a posi-
tive control, whereas rTat (50 nM) oxidized with 2.5 mM
N,N,N,N-tetramethylazodicarboxamide (diamide; Sigma)
was used as a negative control.
Mechanism-based Affinity Chromatography—A Sepharose
affinity matrix was prepared with two mutant forms of His-
tagged human TR1 where the resolving Cys and Sec in the C
terminus were replaced with Ser in one (denoted as SU) and
both Cys and SeCys to Ser in the other (denoted as SS) as
described earlier (15). The immobilized enzymes were initially
incubated with 2 ml of 0.5 mM NADPH in phosphate-buffered
saline for 20 min. 15 g of rTat was applied to each column.
After 1 h of incubation at room temperature on an end-over
shaker, the resins were washed 5 times with phosphate-buff-
ered saline (PBS) to remove nonspecifically bound rTat and
then eluted with 500 l of PBS containing 10 mM DTT. All the
flow-through (wash) and eluate fractions were concentrated
and analyzed for the presence of Tat using Western blots.
RESULTS
Selenium Inhibits HIV-1 Transcription—An inverse correla-
tion between selenium levels and HIV progression has been
reported (7). To gain insight into mechanisms by which sele-
nium inhibits HIV replication, we tested whether Tat-depend-
ent HIV transcription was sensitive to changes in cellular sele-
nium status. The human monocytic cell line U937, cultured
under selenium-deficient conditions (containing 7 nM sele-
nium), were supplemented with selenium at 0.05–1.0 M. Cells
were co-transfected with pCI-Tat and LTR-Luc reporter that
contained the TAR element. Selenium at concentrations of 100
nM significantly reduced Tat-dependent transcription com-
pared with the cells where no exogenous selenium was added
(Fig. 1). Tat was required for selenium-dependent repression of
LTR-Luc activity as seleniumhad negligible effect on basal LTR
activity in the absence of Tat. Furthermore, selenium had no
effect on the TARLTR-Luc (data not shown). Similar repres-
sion of Tat-dependent LTR activity was observed in human
MDMs, although the amount of selenium added was 500 nM
(Fig. 1A, inset). Selenium also inhibited HIV-1 replication as
determined by p24 ELISA (Fig. 1A). HIV-infected U937 cells
cultured in the absence of selenium produced 6-fold more
virus than infected cells cultured in the presence of selenium.
Maximum suppression of HIV-1 replication was observed at
0.1M selenium, which was the concentration that repressed
Tat-dependent LTR activity. To ensure that we were effectively
depleting selenium, the expression of two selenoproteins, TR1
and GPX1, was monitored.We observed a decrease in TR1 and
GPX1 expression in U937 cells (Fig. 1B) and primary MDM
cells (data not shown) that were cultured under selenium-defi-
cient conditions. Selenium supplementation rescued TR1
activity (Fig. 1A) and expression (Fig. 1B) in U937 cells. The
enzymatic activity of TR1 and expression of TR1 and GPX1
were saturated at 100 nM selenium, which corresponded to
the concentration that fully inhibited Tat-dependent LTR
activity, suggesting an inverse relationship between HIV-1
transcription and selenoprotein activity.
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HIV-1 Infection of Macrophages Down-regulates TR1
Expression—Selenium is incorporated as Sec into enzymes
such as the glutathione peroxidases and TRs that control cellu-
lar redox homeostasis. Based on cellular localization and func-
tion, we focused on the cytosolic TR1 form (also called
TXNRD1 or TrxR1) rather than the thioredoxin/glutathione
reductase (TR2 or TrxR3) or themitochondrial TR3 (TXNRD2
or TrxR2) (15). To determine whether HIV-1 infection led to
changes in TR expression, as reported earlier in T-cells (12),
primary MDM were infected with HIV-1 and TR1 levels were
monitored by immunoblotting. There was 85% decrease in
TR1 expression within 48 h of HIV-1 infection (Fig. 2), suggest-
ing that HIV-1 could potentially target selenoproteins, in-
cluding TR1, to ensure generation
of oxidative stress for efficient
replication.
TR1 Negatively Regulates HIV-1
Transcription and Replication—The
inverse correlation between TR1
activity and HIV-1 transcription
and replication suggested that TR1
is a negative regulator of HIV-1
transcription. To investigate the
role of TR1 in regulating Tat-medi-
ated HIV-1 transcription, ebselen, a
highly active substrate of TR (33,
34), was used to “hijack” TR activity.
As shown in Fig. 3A, ebselen
increased Tat-dependent transacti-
vation of the HIV-LTR by 4-fold.
The ability of ebselen to enhance
transcription required Tat and the
TAR element (Fig. 3A). In addition,
we used siRNA to specifically
diminish TR1 expression in U937
cells and MDM (Fig. 3B). TR1
siRNA depleted 80% of TR1 in
MDMs and U937 cells as deter-
mined by immunoblots (Fig. 3C). In
U937 cells and MDMs treated with
TR1 siRNA, Tat-dependent LTR-
Luc activity was increased by 8- and
4-fold, respectively (Fig. 3B). Furthermore, the decrease in TR1
did not ectopically activate NF-B or enhance NF-B-depend-
ent transcription, as reducing TR1 expression and activity with
siRNA or ebselen did not significantly alter activity of LTRs
lacking NF-B sites (Fig. 3D) or TAR (data not shown). To
determine whether decreasing TR1 had an impact on HIV-1
provirus transcription and replication, we infected cells with
HIV-Luc, a replication incompetent HIV-1 clone in which Env
was replacedwith a luciferase reporter gene (35). Provirus tran-
scription was monitored by measuring luciferase activity. Con-
sistent with the transient transfection data, we observed a 3.5-
fold increase in HIV-1 provirus transcription in U937 cells
whenTR1was diminished by siRNA comparedwith the si-con-
trol (Fig. 4A). In addition,MDMswere infectedwith replication
competent HIV-1, and virus replication was monitored by p24
ELISA (Fig. 4B). A 3.5-fold increase in HIV replication was
observed in MDMs that were transfected with TR1 siRNA. A
similar increase was also observed inHIV-1 replication inU937
cells that were treated with 5 M ebselen (Fig. 4C). Taken
together, these results indicate that TR1 impacts HIV-1 tran-
scription and replication by repressing the activity of Tat.
In Vitro Reduction of rTat by TR1—Tat has a Cys-rich region
with three Cys-Xaa-Xaa-Cys motifs in the transactivation
domain (23). Previously, increased transactivation of a LTR-
Luc reporter was demonstrated by bacterially expressed rTat
that was allowed to slowly refold in the presence of a reducing
agent (tris[2-carboxyethyl]phosphine), indicating that the for-
mation of intramolecular disulfide bonds was necessary for Tat
function (36). Using an identical protocol, our studies also dem-
FIGURE 1. Selenium inhibits Tat-dependent LTR activity in humanmacrophages. A, U937 cells were trans-
fected with 2 g of LTR-Luc and then incubated with different concentrations of selenium (0.05–1.0 M) for
72 h. Cells were lysed, and luciferase activity was measured as an indication of HIV-LTR activity. Transfections
were performed in triplicate, and data are presented as the percentage of luciferase. Inset, the same experi-
ment performed with primary human MDMs. These cells were transfected with LTR-Luc, pCI-Tat, or empty
vector using the Amaxa nucleofector system. TR activity wasmeasured in the U937 cell lysates. For replication
experiments, 1.0106 U937 cells were cultured in a selenium-deficientmedia and infectedwithHXB.2 for 24 h
followed by media changes containing selenium from 0.05 M to 1 M. After 3 days the culture media super-
natants were used to measure p24 levels. B, modulation of expression of selenoproteins (TR1 and GPX1) by
exogenous selenium in macrophages. U937 cells cultured in low-selenium serum-containing media (7 nM
selenium) were passaged for 3–5 days in media containing 0.025–0.25 M selenium (as sodium selenite). The
cell lysates were analyzed for GPX1 and TR1 expression. Membranes were stripped and reprobed with glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) to normalize for protein loading. Densitometric evaluation of
the data is shown. Representative of n 3. *, p	 0.005. IB, immunoblot.
FIGURE 2. Infection of MDMs by HIV-1 decreases the expression of TR1.
Human monocyte-derived macrophages were infected with HXB.2 for 48 h.
Cells were lysed, and TR1 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were detected by immunoblotting (IB). Results are representative of
n 3 shown.
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onstrated that refolded rTat, which is efficiently taken up by
cells (37), was able to activate TAR-dependent transcription in
U937 cells, whereas rTat treatment did not activate the pSV2-
Luc reporter, which lacks the LTR (Fig. 5). Furthermore, to
demonstrate that rTat is a substrate for TR1, we used an in vitro
assay with rat liver TR1 to assess the formation of free thiols
from disulfide bonds using Ellman reagent (5,5-dithiobis(2-
nitrobenzoic acid)). Coincubation of rTatwith rat liverTR1 and
NADPH increased the number of free thiols from three to
seven, indicating that four out of the seven Cys in Tat form two
disulfide bonds (Fig. 6A). RedoxWestern blot analysis was used
to examine the electrophoreticmobility of rTat before and after
reduction by TR1. AMS-modified proteins increased protein
mass by 500 Da, which can be detected as a modest shift on a
non-reducing and non-denaturing PAGE. The results indicate
an upward shift in the mobility of rTat as a result of reduction
by TR1, similar to the DTT-reduced rTat control (Fig. 6B). To
further confirm this observation, selenium supplementation of
Jurkat T-cells that stably expressed Tat showed a dose-depend-
ent change in the redox status of Tat with increase in selenium
(data not shown). We also used a spectrophotometric assay to
examine the oxidation of NADPH and observed that rat liver
TR1 catalyzed the NADPH-de-
pendent reduction of rTat in vitro.
The reduction followed typical
Michaelis-Menten kinetics (data
not shown). Finally, we used a
mechanism-based affinity chro-
matographic approach to demon-
strate that human TR1, where the
resolving Cys was mutated to Ser
(denoted as SU), was able to bind to
rTat. Although there was some pro-
tein seen in the flow-through frac-
tion, the eluate fraction had a rela-
tively higher amount of rTat (Fig.
6C), which could be due to the satu-
ration of TR1. Using human TR1
where both Cys and SeCys were
mutated to Ser (denoted as SS), we
noticed relatively low levels of rTat
in the eluate fractions, whereas the
flow-through fraction contained
most of rTat (Fig. 6D). Taken
together, these studies suggest that
TR1 reduces disulfides in Tat by a
direct interaction.
DISCUSSION
Epidemiological studies have
shown a correlation between
decreased selenium status and
increased mortality and morbidity
ofHIVpatients (4, 38, 39). However,
there is sparse information regard-
ing mechanisms by which selenium
influences HIV-1 replication. Sele-
nium decreases oxidative stress in
HIV-infected people by neutralizing highly reactive pro-oxi-
dant species via selenoenzymes, which is thought to positively
impact patient immune function and health (11) and, thus,
indirectly influence HIV-1 replication in infected cells. Based
on our data, selenium appears to have a direct effect on HIV-1
transcription leading to decreased virus replication. Alterna-
tively, selenium may directly regulate HIV-1 transcription by
activating NF-B, which is required for efficient provirus tran-
scription. In this report, we present data indicating that sele-
nium, through the selenoprotein TR1, negatively regulates
HIV-1 transcription by targeting Tat-dependent transcription
independent of NF-B.
Tat is essential for HIV-1 replication and is required for effi-
cient transcription elongation (40). HIV-1 Tat binds the RNA
stem loop structure formed by TAR and recruits the positive
transcription elongation factor, P-TEFb, to the LTR, which
enhances processive transcription. Because Tat is necessary for
HIV-1 replication, host mechanisms that specifically target its
activity would provide attractive therapeutic options that
would be complementary to current anti-retroviral treatments
targeting reverse transcriptase, integrase, and protease
enzymes. The conclusion that the intramolecular disulfide
FIGURE 3. Down-regulation of TR1 activity and expression increases Tat-dependent transcription.
A, ebselen treatment ofmacrophages increases Tat-dependent transcription. U937 cells were transfectedwith
LTR-Luc orTARLTR-Luc and pCI-Tat or empty pCI vectors. The transfected cells were cultured in the presence
or absence of ebselen (5 M) or DMSO (0.1% v/v) for 24 h. Luciferase activities in the lysates were quantitated
after 48 h post-transfection and normalized to total protein. B, U937 cells were transfected with LTR-Luc and
pCI-Tat or empty pCI vector and TR1 siRNA or si-control. Luciferase activities were measured as mentioned
earlier. MDMswere transfected with LTR-Luc and pCI-Tat or empty pCI vector and TR1 siRNA using the Amaxa
nucleofector system and processed as described earlier. C, TR1 expression in TR1 siRNA or si-control-treated
U937 andMDM cells as determined by immunoblotting (IB). The blots were stripped and reprobedwith either
-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Densitometric values are shown below each
panel. D, TR1 regulates Tat-dependent transcription independent of NF-B. U937 cells were transfected with
BLTR-Luc andpCI-Tat or emptypCI vector. Cellswere then either treatedwith ebselen (5M) or TR1 siRNAor
si-control. Cell lysates were used in luciferase activities 48 h post-transfection. The luciferase activity was
normalized to total cell protein. *, p	 0.05.
TR1 Negatively Regulates Tat-dependent Transcription
NOVEMBER 28, 2008•VOLUME 283•NUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 33187
 by guest, on April 12, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
bonds are critical for Tat function is consistent with previous
observations that reducing agents that disrupt intramolecular
disulfide bonds inhibit Tat activity (25). Our results not only
support earlier data but also demonstrate that TR1 negatively
regulates Tat activity by reducing two disulfide bonds in Tat.
Although the Cys-rich domain is not structurally well defined,
recent NMR studies using recombinant Tat protein confirm
that the disulfide bonds are essential for stabilizing its structure
to possibly allow the cyclin T1 subunit of P-TEFb to bind Tat
(41). Therefore, TR-dependent
reduction of the disulfides may
affect the interaction of Tat with
P-TEFb, leading to a decrease in the
transcription processivity. The role
of individual Cys residues in the for-
mation of disulfide bonds and the
reactivity of TR1 toward various
Cys mutant Tat proteins is being
currently explored. Our results also
indicate that Tat is a redox-sensing
molecule, as it is subjected to nega-
tive regulation by enzymes such as
TR1. Although the mechanism-
based affinity chromatography ex-
periments suggest a direct inter-
action between Tat and TR1, it is
plausible that the redox modulation
could also occur through TRmodu-
lation of Trx, as is the case for
NF-B p65 subunit (42) and glu-
cocorticoid receptor (43). However,
this latter mechanism is indirect,
differing from the direct TR1-Tat
interactions that our data suggest.
Specifically inhibiting TR1 activ-
ity in macrophages with either a
high affinity substrate or expression
using siRNA resulted in more effi-
cient HIV-1 replication. If oxidative
stress is required for efficient HIV-1
replication, then the virus would be
expected to circumvent the reducing activities of TR. Seleno-
proteins, includingTR1, are down-regulated uponHIV-1 infec-
tion and during the progression of AIDS and associated dis-
eases.Whether HIV-1 directly alters the redox status of the cell
or indirectly promotes inflammation and oxidative stress is not
clear; however, we show that infection of macrophages
decreases TR1 protein, which is consistent with earlier reports
(12). Moreover, our data demonstrate that the expression of
selenoproteins TR1 and GPX1 in U937 cells andMDMs can be
modulated with selenium (Fig. 1D), providing a strategy to res-
cue selenoprotein expression as well as decreasing HIV-1 tran-
scription and replication in HIV-1 infected cells. Although
these studies have focused on HIV-1, we would speculate that
viruses in general would have mechanisms for sensing the oxi-
dative status of its host cell. For example, we have preliminary
data indicating that replication of the parainfluenza virus type
5, a non-segmented negative strand RNA virus, is repressed by
selenium supplementation (data not shown).We have not fully
characterized how selenium inhibits parainfluenza virus type 5
replication, but it is interesting to note that this virus does
encode a Cys-rich protein that could be potentially targeted by
TR1.
In conclusion, we have identified TR1 as a critical host sel-
enoprotein that plays a pivotal role in repressing HIV-1 tran-
scription by modulating the redox-status of the key viral pro-
tein, Tat (Fig. 7). It remains to be seen if the redox status of Tat
FIGURE 4.TR1negatively regulatesHIV-1 replication inprimarymonocyte-derived-macrophages.A, TR1
negatively regulates HIV-1 provirus transcription. U937 cells were infected with HIV-Luc virus. Cells (12–24
post-infection)were transfectedwith TR1 siRNA. Luciferase activitywasmeasured72hpost-infection.B,MDMs
were infected with HXB.2. 12–24 h post-infection cells were transfected with TR1 siRNA or si-control using the
Amaxa nucleofector system and subjected to luciferase assay 3–5 days post-infection. C, ebselen treatment
increases HIV-1 replication. U937 cells were infected with HXB.2. The transfected cells were cultured in the
presence or absence of ebselen (5 M) or DMSO (0.1% v/v). Supernatants were collected at 4 days post-
infection and assayed for viral replication by p24 ELISA. Each data point represents three independent infec-
tions, and error bars show the S.D. of these replicates. *, p	 0.05.
FIGURE 5. Expression, purification, and biological activity rTat. A, electro-
phoretic purity of rTat expressed in E. coli using SDS-PAGE. B, U937 cells were
transfectedwith2gof LTR-LucorpSV2-Luc reporter constructs. Transfected
cells were cultured in the presence and absence of 2g rTat protein. Lucifer-
ase activity was measured 48 h post-transfection as an indication of proviral
transcription. After transfections, trypan blue stainingwas performed to con-
trol for cell viability. *, p	 0.05.
TR1 Negatively Regulates Tat-dependent Transcription
33188 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 48•NOVEMBER 28, 2008
 by guest, on April 12, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
correlates with the plasma selenium inHIV-1 seropositive indi-
viduals. Such studies are necessary to understand the therapeu-
tic benefits of selenium as an adjuvant in the management of
HIV/AIDS. These studies partially elucidate onemechanism by
which selenium inhibits HIV-1 replication. Furthermore, these
findings suggest that administration of selenium toHIV-1 sero-
positive individuals at a daily recommended intake of 55
g/day, as per the National Institute of Medicine, may provide
an effective method to slow the progression of AIDS, reduce
morbidity, and enhance survival partly through the redox-de-
pendent regulation of Tat-dependent transcription. Such sup-
plementation studies need to be evaluated with caution given
the toxicity associated with selenium, seen in the form of nau-
sea, blotchy nails, vomiting, and diarrhea at doses higher than
the tolerable upper intake levels of 400 g/day. However,
understanding the mechanism of action of selenium will allow
more direct targets to be examined and set optimal doses to
mitigate toxicity and achieve the desired effect.
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